STAT Plus: Early blood cancer trial is shuttered, possibly dimming hopes for promising therapy
ED UTHMAN/CREATIVE COMMONS
The experimental drug was part of a new class of therapies meant to kill tumors by blocking the protein, which is called CD47.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario